Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

93.19
+0.63000.68%
Pre-market: 92.97-0.2200-0.24%08:07 EST
Volume:13.12M
Turnover:1.22B
Market Cap:235.40B
PE:13.83
High:93.45
Open:91.08
Low:90.50
Close:92.56
Loading ...

Merck expects cancer therapy to be part of government price setting in 2026

Reuters
·
26 Feb

Merck & Co Inc: Expects Keytruda to Be Selected in 2026 for Government Price Setting, Which Would Become Effective on Jan 1, 2028 - SEC Filing

THOMSON REUTERS
·
26 Feb

Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Maybe The Ultimate Laggard’

Insider Monkey
·
26 Feb

Merck Gets Speedy FDA Review of Keytruda in Certain Head, Neck Cancers

Dow Jones
·
25 Feb

Merck's New Supplemental Biologics Application for Keytruda in Head, Neck Cancer Granted Priority Review by FDA

MT Newswires Live
·
25 Feb

FDA Grants Priority Review to Merck’s Application for Keytruda® (Pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS
·
25 Feb

Merck & Co Inc: FDA Has Set a Prescription Drug User Fee Act (Pdufa), or Target Action, Date of June 23

THOMSON REUTERS
·
25 Feb

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Business Wire
·
25 Feb

Nike, Travelers Share Gains Contribute To Dow's Nearly 125-Point Climb

Dow Jones
·
25 Feb

5 Stocks in the Dow ETF That Survived the Worst Week Since October

Zacks
·
24 Feb

Positive Outlook for Merck & Co. Driven by Winrevair’s Success and Favorable Trial Results

TIPRANKS
·
24 Feb

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

GlobeNewswire
·
24 Feb

Merck to Participate in the TD Cowen 45th Annual Health Care Conference

Business Wire
·
24 Feb

Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos

Dow Jones
·
24 Feb

BUZZ-Summit Therapeutics rises on clinical trial collaboration with Pfizer

Reuters
·
24 Feb

3 Magnificent S&P 500 Dividend Stocks Down 36% to 64% to Buy and Hold Forever

Motley Fool
·
24 Feb